Please type a plus sign (+) inside this box -> 7 Under the Paperwork Reduction Act of 1995, no pageons are required to

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

spond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

PADEMAR

(use as many sheets as necessary)

of Sheet

Co	mplete if Known
Application Number	
Filing Date	
First Named Inventor	
Group Art Unit	1646 /652
Examiner Name	BAWA, Rr
Attorney Docket Number	

		_	U.S. PATENT DOCU	JMENTS	
Examiner Initials	Cite No.1	U.S. Patent Document Kind Code ² (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Reievani Passages or Bolevant Figures Appear
		6,264,945	Fischetti et al.	07-24-2001	
		6,254,866	Fischetti et al	07-03-2001	
		6,248,324	Fischetti et al	06-19-2001	<u></u>
		6,238,661	Fischetti et al.	05-29-2001	
		6,056,955	Fischotti et al	05-02-2000	
		6,056,954	Fischetti et al.	95-02-2000	
		6,017,528	Fischetti et al.	01-25-2000	
		5,997,862	Fischetti et al.	- 12-07-1999 -	
		5,985,271	Fischetti etal.		
		5,688,501	Merribet al.	11-18-1997	
		4,957,686	Norris		
		5,604,109	Fischetti et al.	02-18-1997	
		5,882,631	Suga et al.	03-16-1999	
		_5,741,487	Asai et al.	04-21-1998-	
		6,113,887		09-05-2000-	
		4,122,158	Schmitt	10-24-1978	
			Schmitt		
		-6,113,887	Mori et al.	09-05-2000	·
		-4,885,163 -	Shaar et al	12-05-1989	

				FORE	IGN PATENT DOCUMEN	TS		
Examiner	Cite		Foreign Patent Doc		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	Т
Initials	No.1	Office ³	Number ⁴ .	Kind Code ^s (<i>il known</i>)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Pelevant Electes Appear	Τ°
			WO 97 0235	1 A	LCIBA GEIGY AG, eta	01-9	ı !3-1997-	
			WO 96 0732	9 A	UNIV. MARYLAND	03-	14-1996	1
			EP 0 510 90	ŽA -	AGRICULTURAL & I	FOOD RES_10-2	8-1992	+
		╁╌┼	_ -WO 99 0480	9 A	AMBI INC		4-1999	╁
		 						十
				·				I
						<u> </u>		_
				L 1				1.

Examiner	Da	ate	
Signature	Co	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

	•	JAN 11	3002 A
Plea	use type a plus sign (+) inside this bo	ox →	NE CO
Und	der the Paperwork Reduction Act of	1995, no persons are 40	fired to resp

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

Co	mplete if Known	
Application Number		
Filing Date		
First Named Inventor		
Group Art Unit	1619 /652	
Examiner Name	BAWA	
Attorney Docket Number	-	

				U.S. PATENT DOCU	UMENTS	
examiner nitials*	Cite No.1	U.S. Paten Number	Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-XXYY	Pages, Columns, Lines, Where Relevant Passages or Relevant
			(# known)		MINI-OLDIATTY	Figures Appear
		6,177,55		Woo et al.	01-23-2001	
		-6,187,75		Clackson et al.	02 13 2001	
$\neg \uparrow$		6,132,97	0 - -	Stemmer	10-17-2000	
		<u>5,162,22</u> 6	6	Beachey et al.	11-10-1992	
		_ 6,335,01	2	Fisehetti et al.	01-01-2002	
		- 6,326,00			12-04-2001	
		- 6,217,39	9-1-1	Fischetti et al	- 08-21-2001	
	-			· · · · · · · · · · · · · · · · · · ·	- 	
+					 	
						
				······································		
						
						
						
						

				FORE	IGN PATENT DOCUMENT	rs		
Examiner Cit	Cite	F	oreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	Π
Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (# known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T6
						1		
								_
								<u> </u>
								<u> </u>
								<u> </u>
								<u> </u>
l i		ii		1 1		1. 1		1

Examiner	·	Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Palent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁸ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	JAN 1 1 2002 E
Please type a plus sign (+) inside this box → ☐ 1	e reduced despond to
Substitute for form 1449B/PTO	

Sheet

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE a collection of information unless it contains a valid OMB control number.

Substitute for form 1/498/PTO		Complete if Known				
	NEORMATION DISCLOSURE TATEMENT BY APPLICANT	i	Application Number			
				Filing Date		
				First Named Inventor		
STATEMENT BY APPLICANT	ALLEIVANI	Group Art Unit	1619 1652			
(use as many sheets as necessary)		Examiner Name	BAWA			
heet	T	of	5	Attorney Docket Number		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Reisenger, et al. (1998) "Characterization of Escherichia coli lysis using a family of chimeric E-L Genes" Fems Microbiol Letter. 164(1) p.159-167	i
Sheehan MM, et al. (1997) "The lytic enzyme of the Pneumococcal Phage Dp-1: a chimeric lysis of intergeneric origin." Mol. Microbiol. 25(4) p. 717-7	25-
Young et al. (2000) "Phages will out: stragegies of host cell lysis." Trends in Microbiology. 8(4) p. 120-127	
Garcia et al.(1997) "The Pneumococcal cell wall degrading enzymes: A modular design to create new lysins?" Microb. Drug Resist. 3(2): p. 199-2	11
Sheehan MM, et al., (1997) "The Lytic Enzyme of the Pneumococcal Phage I a Chimeric Lysin of Intergeneric Origin" Mol. Microbiol. 25(4) p. 717-25	Эp-
Garcia P, et al. (1997) "Bacteriophages of Streptococcus pneumoniae: a mole approach" Microb. Drug Resist. 3(20) 165-76.	cul
Sheehan, MM, et al.(1996) "Analysis of the catalytic domain of the lysin of t lactococcal bacteriophage Tue2009 by chimeric gene assembling." FEMS Microbiol.Lett. 14(1): p. 23-28.	he
Sanz, JM, et al. (1996) "Construction of a multifunctional pneumococcal murein hydrolase by module assembly." Eur. J. Biochem. 235(3):601-5	
Lopez R, et al. (1995) "Architecture and Domain Interchange of the Pneumoeoccal Cell Wall Lytic Enzymes" Dev. Biol. Stand. 85 p. 273-81.	-
1	Lopez R, et al. (1995) "Architecture and Domain Interchange of the

			T
Examiner	$\Omega \Lambda$	Date	
		Concidered	04-26-04
Signature	A STATE OF THE STA	Considered	07 25 04

*EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

•—	!				
	P	JAN	1	1	20
	_				

5

of

Sheet

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box ->	Approved for use through 10/31/2002. OMB 0651-00. U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERS. U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERS. U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERS. U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERS. Compared to 15 K Frown.	
	Complete if Known	
Substitute for form 1449B/PTO	Application Number	_
INFORMATION DISCLOSURE	Filing Date	-
STATEMENT BY APPLICANT	First Named Inventor	_
STATEMENT BY AFTERNAM	Group Art Unit 1619 /652	
(use as many sheets as necessary)	Examiner Name BAWA	_
Cost as many shoots	Attorney Docket Number	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the litem (book, magazine, journal, sensit, symposium, catalog, etc.), date, page(s), volume-issue number(s), item (book, magazine, journal, sensit, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T2
111111111		Crown et al (1993) "Interchange of Functional Domains Switches Enzymes	
	1	Specificity: Contstruction of a chimeric pneumococcal-closeridial	
	-	cell wall lytic enzyme." Mol. Microbiology. 9(3) p. 1019223.	
	1	Diaz, E. et al. (1990) "Chimeric phage-bacterial enzymes: a clue to	-
		the modular evolution of genes. PNAS. 87(20) p. 8125-9.	
	ļ. <u> </u>	Diaz, E. et al.(1990) "Chimeric pneumoccal cell wall lytic enzymes reveal important physiological and evolutionary traits."	
	+-	J. Biol. Chem. 266(9) p. 5464-71.	
		Lopez, et al. (1997) "The preumococcal cell wall degrading enzymes:	+-
		A modular design to create new lysins?" Microbiological Drug Resistance, 3(2) p. 199-211.	
		Loessner, et al. (1999) Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of Staphylococcus aureus Bacteriophage. (1999) Journal of Bacteriology, 181(15) p. 4452-4460.	ed " –
		Witte, A et al. (1998) "Characterization of Escherichia coli lysis using a family of chimeric E-L genes." FEMS Microbiol. Lett., 164(1), p. 159-167	
		Martin, Ana C et al (1998): "Functional analysis of the two-gene lysis system of the pneumocoecal phage Cp-1 in homologous and heterologous host cells." Journal of Microbiology 180(2), p. 210-217	
	1	Oki Masaya et al. (1997) "Functional and structural features of the holin HOL protein of the Lactobacillus plantarum phage phi-gle: Analysis in Escherichia coli system." Gene (AMSTERDAM) 197(1-2) p 137-145.	

	Date	
Examiner	Considered	
Signature	00	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) Inside this box

Under the Paperwork Reduction Act of 1995, no person are required to appoint

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitu	te for form 1449B/P	TO.	VAUL -	Com	plete if Known
		-		Application Number	
INFO	DRMATIO)N D	ISCLOSURE	Filing Date	
STATEMENT BY APPLICANT				First Named Inventor	
917		₩,		Group Art Unit	1649 1652
	(use as man)	y sheet	s as necessary)	Examiner Name	RAWA-
Sheet	5	of	5	Attorney Docket Number	
					

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), jittle of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city author country where published.	72
		Young, Ry et al. (2000) "Phages will out: strategies of host cell lysis." Trends in Microbiology, 8(3) p 120-127.	-
	_	Nelson, et al. (2001) "Prevention and elimination of upper respiratory colonization of mice by Group A Streptococci by using a bacteriophage	
		lytic enzyme! PNAS. 98 (7) p. 4107-4112	
		Garcia, et al. (1987) Purification and biochemical characterization of the pneumococcal bacteriophage Cp-1 lysin." Journal of Virology 61(8)	
		Loessner, et al. (1996) "Modified Listeria bacteriophage lysin genes (ply)	
		allow efficient overexpression and one-step purification of biochemically active fusion proteins." Applied and Environmental Microbiology. 62(8) p. 3057-3060	

Examiner	·	Date	
Signature		Considered	ı

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

Sheet

ENT & TRI INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

Under the Paperwork Reduction Act of 1998

Approved for use through 10/31/2002. OMB 0651-0031

LU.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use through 10/31/2002. OMB 0651-0031

Complete if Vacnation unless it contains a ...

mation unless it contains a ... Application Number Filing Date First Named Inventor Group Art Unit

(use as many sheets as necessary)

Examiner Name Attorney Docket Number

	U.S. PATENT DOCUMENTS					
	xaminer Cite Document Number		-	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan
Examiner Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
DUS -	1	US- 6056954	05/02/00	Fischetti, et al.		
	2	US- 5997862	12/07/99	Fischetti, et al.		
	3	US- 5985271	11/16/99	Fischetti, et al.		
	4	US- 5688501	11/18/97	Merril, et al.		
	5	US- 4742981	05/10/88	Converse		
1	6	US- 2019789	11/05/35	Mahannah		
	7	US- 2763931	09/25/58	McMillan		
1	8	US- 5479732	01/02/96	Burtch, et al.		
	9	US- 3465445	09/09/69	Fisher		
	10	US- 2315260	03/30/43	Lancaster		
_	11	US- 5604109	02/18/97	Fischetti, et al.		
1	12	US- 5260292	11/09/93	Robinson, et al.		
+	13	US- 4957686	09/18/90	Norris		
1-	14	US- 6017528	01/25/00	Fischetti, et al.		
+-	15	US- 6132970	10/17/00	Stemmer		
 	16	US- 3852424	12/03/74	Gaeumann, et al.		
+	17	US- 6264945	07/24/01	Fischetti, et al.		
1,	18	US- 6254866	07/03/01	Fischetti, et al.		
1/	19	US- 6248324	06/19/01	Fischetti, et al.		
צוח	20	US- 6238661	05/29/01	Fischetti, et al.		

	FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	Cite No.1	Country Code ² - Number ⁴ - Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	۳⁵		
DJS	21	EP-0510907 A 2	10/28/92	Agricultural & Food Res.				
	22	WO-9702351	01/23/97	CIBA Geigy AG, et al.				
	23	WO-9607329	03/14/96	Univ. Maryland				
	24	WO-9904809	02/04/99	Ambi, Inc.				
	25	FR-2357246	02/03/78	Martinez				
	26	WO-9531562	11/23/95	Quest Inernational B.V.				
	27	EP-587541 A1	03/16/94	Tecnogen ScpA				
m/c -	 	ļ		 				

Examiner Signature	Af-	Date Considered	04-26-04

^{&#}x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

JUN 1 2003

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no psipons are or form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Sheet

(use as many sheets as necessary)

of 11 2

TRADEMA	Complete if Known
Application Number	09/960,472
Filing Date	09/21/01
First Named Inventor	Vincent Fischetti
Group Art Unit	1652
Examiner Name	David J. Steadman
Attorney Docket Number	

			U.S. PATENT	DOCUMENTS	
Examiner Cit	er Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Reimant
Initials	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	CIEU DOCUMENT	Passages or Relevant Figures Appear
ממ	28	US- 6056955	05/02/00	Fischetti, et al.	
7	29	US- 5882631	03/16/99	Suga, et al.	li i
1	30	US- 5741487	04/21/98	Asai, et al.	90/
	31	U\$- 6113887	09/05/00	Mori, et al.	Train
1	32	US- 4122158	10/24/78	Schmitt	IEUH CEA
_	33	US- 3983209	09/28/76	Schmitt	OL)
T	34	US- 4885163	12/05/89	Shaar, et al.	
1	35	US- 6177554	01/23/01	Woo, et al.	
1	36	US- 6187757	02/13/01	Clackson, et al.	
1	37	US- 5162226	11/10/92	Beachey, et al.	:
1	38	US- 6335012	01/01/02	Fischetti, et al.	
\top	39	US- 6326002	12/04/01	Fischetti, et al.	
1	40	US-6277399	08/21/01	Fischetti, et al.	
\top	41	US-4062941	12/13/77	Davies	
1	42	US-5571687	11/05/96	Chu, et al.	
1	43	US-5514602	05/07/96	Brooks Jr, et al.	
1	44	US-5500350	03/19/96	Baker, et al.	
7	45	US-5384265	01/24/95	Kidwell, et al.	
Va	46	US-4361537	11/30/82	Deutsch, et al.	
מנת	47	US- 5120643	06/09/92	Ching, et al.	

	FOREIGN PA	TENT DOCU	MENTS		
Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁶ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
48	WO-9323544	11/25/93	The University Court of the University of Glasgow		
49	EP-0293249 A1	11/30/88	Amrad Corporation Limited		
50	EP-0646646 A2	04/05/95	Bristol-Myers Squibb Company		
51	EP-0359873 A1	03/28/90	The Public Health Research Inst. of the City of New York		
				 	
	 				
	1				
	48 49 50	Foreign Patent Document	Cite No.1 Foreign Patent Document Publication Oate MM-DD-YYYY 48 WO-9323544 11/25/93 49 EP-0293249 A1 11/30/88 50 EP-0646646 A2 04/05/95	Cite No. Country Code - Number - Kind Code (# known) Number - Kind Code (# known) Number - Kind Code (# known) Number - Kind Code Number Numbe	Cite No.¹ Foreign Patent Document Country Code¹ - Number⁴ - Kind Code⁴ (if known) 48 WO-9323544 Publication Date MM-DO-YYYY The University Court of the University Corporation Limited EP-0293249 A1 11/30/88 EP-0466646 A2 Publication Date MM-DO-YYYY The University Court of the University Corporation Limited Bristof-Myers Squibb Company The Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear The University Court of the University Court of the University of Glasgow Amrad Corporation Limited Bristof-Myers Squibb Company The Public Health Health Health Health Research Inst.

Examiner Signature	Af-	Date Considered	04-26-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE or respond to a collection of information unless it contains a valid OMB control number.

trol number. Under the Paperwork Reduction Act of 1995, no persons are I

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet of | 11

	Complete if Known
Application Number	09/960,472
Filing Date	09/21/01
First Named Inventor	Vincent Fischetti
Group Art Unit	1652
Examiner Name	David J. Steadman
Attorney Docket Number	

			U.S. PATENT I	DOCUMENTS	
Examiner Initials	Cite No.1	Document Number Number - Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
7775	52	US-4948726	08/14/90	Longoria	Figures Appear
<u>ш</u> э_	53	US- 4459381	07/10/84	Gefter	
┼	54	US- 4552839	11/12/85	Gould, et al.	**
 	55	US- 4313734	02/02/82	Leuvering	JUN
+	58	US- 4847199	07/11/89	Snyder, et al.	7 m.
1	57	US- 4497900	02/05/85	Abram, et al.	IECH CENT
1	58	US- 4707543	11/17/87	Zollinger, et al.	-1, OE/V/
†	59	US- 5763251	06/09/98	Gasson	
1	60	US- 6159688	12/12/00	Borchert, et al.	
1	61	US- 4784948	11/15/88	Scott, et al.	
1	62	US- 5760026	06/02/98	Blackburn, et al.	
7	63	US- 5602040	02/11/97	May, et al.	
	64	US-4521252	06/04/85	Miyake, et al.	
7	65	US-4355022	10/19/82	Rabussay	
	66	US- 4115546	09/19/78	Vidra, et al.	
	67	US- 4116327	09/26/78	Eglinton, et al.	
	66	US- 3929994	12/30/75	Hirsch, et al.	
	69	US- 6083684	07/04/00	Gasson	·
V	70	US-5360617	11/01/94	Gasson	
7225	71	US- 5079174	01/07/92	Buck, et al.	

		FOREIGN PA	TENT DOCU	MENTS		
	T	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	τ°
						
		<u> </u>			<u> </u>	
					}	
			ļ	L	ļ	
	ļ				ļ	
	 _			<u> </u>	 	
		 			 	

		والمراجع المراجع المرا	
Examiner Signature	Of-	Date Considered	04-26-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid ONB control number. Complete if Known Substitute for form 1449A/PTO 09/960,472 **Application Number** INFORMATION DISCLOSURE Filing Date 09/21/01 STATEMENT BY APPLICANT Vincent Fischetti First Named Inventor 1652 Group Art Unit David J. Steadman (use as many sheets as necessary) Examiner Name Attorney Docket Number of 11 Sheet U.S. PATENT DOCUMENTS Name of Patentee or Applicant of Cited Document Document Number Pages, Columns, Lines, Where Relevant Publication Date MM-DD-YYYY Examiner Initials * Passages or Relevant Number - Kind Code² (if known) Figures Appear 02/18/97 Baker, et al. 72 03/15/94 Shigekawa, et al. 73 US-5294369 12/13/94 Friedman, et al. US-5372931 74 US-4933185 Wheatley, et al. 06/12/90 75 04/28/92 Allwood, et al. US-5108758 76 12/15/87 Schroder 77 US-4713249 Eden, et al. 78 US-4812445 03/14/89 Short, et al. 11/23/71 79 US-3622677 01/18/83 Trubiano 80 US-4369308 US-5393658 02/28/95 Olsen 81 US-US-US-US-US-US-US US-US-US-**FOREIGN PATENT DOCUMENTS** Pages, Columns, Lines, Foreign Patent Document Name of Patentee or Applicant of Cited Document Cite No.1 Publication Where Relevant Examiner Date MM-DD-YYYY Passages or Relevant initials* Country Code3 - Number4 - Kind Code6 (# known) Te Figures Appear Date

Considered

4-26-04

Examiner

Signature

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

	Under the Paperwork Reduction Act of 1995, no percent	App UAS Patent and Trade	PTO/SB/08B(10- proved for use through 10/31/2002. OMB 0851-00 pmark Office: U.S. DEPARTMENT OF COMMERI of information unless it contains a valid OMB control num	31 I CE
	Substitute for form 1449A/PTO	8 THAUS	Complete if Known Dr	7
		Application Number	09/960,472	FILE
	INFORMATION DISCLOSURE	Filing Date	09/21/01	LINED
	STATEMENT BY APPLICANT	First Named Inventor	Vincent Fischetti JUN	
		Group Art Unit	1652	2003
	(use as many sheets as necessary)	Examiner Name	David J. Steadman LCH CENTE	J
	Sheet 5 of 11	Attorney Docket Number	FINE	71600/2000
7				~~V/&Y(J(J

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ²
DIS	82	KH Nasibulini et al; RU-2103991; Composition for treating streptocessal diseases—comprises purified concentrate of streptococcal bacteriophage, solution of quinsosol, dry landin, albumin and vegetable oil; XP-002141110	
DK	83	LD Demidova et al; RU2064299; Cattle mastitis therapeutic preparation—semprises lyso: amidase of specific lytic activity and mono- and di-basic sodium phosphate(s); XP-002141111	

	,		
Examiner		Date	
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Setent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no person are required to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no person have required to the metion unless it consumers

mplete If Known
09/960,472
09/21/01
Vincent Fischetti
1652
David J. Steadmal CH CENTER 600/2900 PTRADE Complete If Known Substitute for form 1449A/PTO Application Number INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor **Group Art Unit** (use as many sheets as necessary) Examiner Name Attorney Docket Number of 11 6 Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T²
nitials *	No. ¹	number(s), publisher, city and/or country where per country and per country of Medicine, Bethesda, MD, US, Database Accession No. 90297672 Mediine Online, US National Library of Medicine, Bethesda, MD, US, Database Accession No. 90297672 XP002170795, abstract only	
1/15	85	BARTELL, et al., Origin of polysaccharide depolymerase associated with bacteriophage infection, Journal of Virology, March 1969, pp. 290-296, Vol. 3, No. 3	
_	86	BEHNKE, et al., Cloning and expression in Escherichia coli, Bacillus subtilis and Streptococcus sanguis of a gene for staphylokinase - a bacterial plasminogen activator, Mol Gen Genet, December 1987, pp. 528-534, Vol. 210	
	87	BESSEN, et al., Chemical characterization of binding properties of opacity-associated protein II from Neissena BESSEN, et al., Chemical characterization of binding properties of opacity-associated protein II from Neissena	
	88	BIZIULEVICHIUS, et al., In vivo studies on lysosubtilin: 3. Efficacy for treatment of mastitis and superficial lesions of the udder and teats in cows, 1998, Database Biosis Online, Biosciences Information Service, Philadelphia, PA, of the udder and teats in cows, 1998, Database Biosis Online, Biosciences Information Service, Philadelphia, PA, US, Database Accession No. PREV199800492608, XP002183274, abstract only	
_	89	BOIZET, et al., Cloning, expression and sequence analysis of an endolysin-encoding gene of Lactobacillus bulgaricus bacteriophage mv1, Gene, 2000, pp. 61-67, Vol. 94	
_	90	CALDWELL, et al., Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis, Infection and Immunity, March 1981, pp. 1161-1176, Vol. 31, No. 3	
	91	YOUNG et al. Phages will out: strategies of host cell lysis, Trends in Microbiology, Volume 8 No. 3, March 2000, pp 120-127	
	92	CORBEL, et al., Soluble antigens obtained from influenza virus by treatment with non-ionic detergent, J Hyg., Camb., 1970, pp. 81-96, Vol. 88	
	93	CROUX, et al., Interchange of functional domains switches enzymes specificity: construction of a chimeric pneumococcal-clostridial cell wall lytic enzyme, Molecular Microbiology, 1993, pp. 1019-25, Vol. 9, No. 5	
1	94	DIAZ, et al., Chimeric phage-bacterial enzymes: a clue to the modular evolution of genes, Proc. Natl. Acad. Sci. USA, October 1990, pp. 8125-8129, Vol. 87	

Examiner Signature	Date Considered	0.4-26-04 Soo Draw line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, Notingsons	U.S. Patent and Trader are required to respond to a collection of	PTO/SB/08B(10-4 roved for use through 10/31/2002. OMB 0851-00 mark Office; U.S. DEPARTMENT OF COMMER(information unless it contains a valid OMB control num	31 I CE
Substitute for form 1449A/PTO	1000	Complete if Known	7
	Application Number	09/960,472	
INFORMATION DISCLOSURE	Filing Date	09/21/01	FIVE
STATEMENT BY APPLICANT	First Named Inventor	Vincent Fischetti J//A	
•	Group Art Unit	1652	2003
(use as many sheets as necessary)	Examiner Name	David J. Steadman ECH Crass] ~~03
Sheet 7 of 11	Attorney Docket Number	,, OEIVIE	1600/2900

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
DUS	95	DIAZ, et al., Chimeric pneumococcal cell wall lytic enzymes reveal important physiological and evolutionary traits, Journal of Biological Chemistry, March 25, 1991, pp. 5464-5471, Vol. 266, No. 9	
	96	DIXON, et al., Lysostaphin: an enzymatic approach to staphylococcal disease. Ill. Combined lysostaphin- methicillin therapy of established staphylococcal abcesses in mice, The Yale Journal of Biology and Medicine, August 1968, pp. 62-68, Vol. 41, No. 1	
	97	FISCHETTI, et al., Size variation of the M protein in group A streptococci, Journal of Exp. Med., June 1, 1985, pp. 1384-1401, Vol. 161, No. 6	
	98	GARCIA, et al., Bacteriophages of Streptococcus pneumoniae: A molecular approach, Microbial Drug Resistance, Summer 1997, pp. 165-176, Vol. 3, No. 2	
	99	GARCIA, et al., Cloning, purification and biochemical characterization of the pneumococcal bacteriophage Cp-1 tysin, Journal of Virology, August 1987, pp. 2573-2580, Vol. 61, No. 8	
	100	GARCIA, et al., Modular organization of the lytic enzymes of streptococcus pneumoniae and its bacteriophages, Gene, 1990, pp. 81-88, Vol. 86	
	101	GERARDY-SCHANN, et al., Molecular cloning and functional expression of bacteriophage PK1E-encoded endoneuraminidase Endo NE, Molecular Microbiology, May 1985, pp. 441-450, Vol. 16, No. 3	
	102	GOLDBERG, et al., Studies in experimental staphylococcal endocarditis in dogs, Antimicrobial Agents and Chemotherapy, 1967, pp. 45-53	
	103	HARRISON, et al., Lysostaphin in experimental renal infections, Journal of Bacteriology, February 1967, pp. 520-524, Vol. 93, No. 2	
1,	104	HARRISON, et al., Therapeutic activity of tysostaphin in experimental staphylococcal infections, Canadian Journal of Microbiology, January 1967, pp. 93-97, Vol. 13, No. 1	
\ \ \ \ \	105	HAYASHI, et al., Effects of N-Acetylmuramidase from Streptomyces rutgersensis H-46 as a food preservative, Agric. Biol. Chem., December 1989, pp. 3173-3177, Vol. 53, No. 12	

	بصريب سيسم			
	Examiner	10	Date	
1	Signature	100	Considered	04-26-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no passent may be be a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSI

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/960,472

Filing Date 09/21/01

First Named Inventor Vincent Fischetti

Group Art Unit 1652

Examiner Name David J. Steadman

Attorney Docket Number

(use as many sheets as necessary)

Sheet 8 of 11 Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
พร	106	HAYASHIDA, et al., Further characterization of PL-1 phage associated N-acetylmuramidase of Lactobacillus casei, Journal of General Microbiology, May 1987, pp. 1343-1349, Vol. 133, No. 5	
1/10	107	HIGUCHI, et al., Transfection of streptococcus sanguis by phage deoxyribonucleic acid isolated from streptococcus mutans, Infection and Immunity, March 1977, pp. 945-949, Vol. 15, part 3	
1	108	HUAN, et al., Methicillin-resistant staphylococcus aureus infection and its treatment in burned patients, Chinese Journal of Surgery, 1994, Vol. 32, No. 4, abstract	
	109	HUGHEY, et al., Antimicrobial activity of lysozome against bacteria involved in food spoilage and food-borne disease, Applied and Environmental Microbiology, September 1987, pp. 2165-2170, Vol. 53, No. 9	
1	110	KOHLER, Systemic therapy with aerosols Aerosols in Medicine: Principles, Diagnosis and Therapy, 1993, Elseveir Science Publishers, pp. 303-319	
	111	LAWMAN, et al., Molecular cloning of the extracellular endodextranase of streptococcus salivarius, Journal of Bacteriology, December 1991, pp. 7423-7428, Vol. 173, No. 23	
1	112	LOESSNER, et al., Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of staphylococcus aureus bacteriophage 187, Journal of Bacteriology, August 1999, pp. 4452-4460, Vol. 181, No. 15	
1	113	LOESSNER, et al., Modified listeria bacteriophage lysin genes (ply) allow efficient overexpression and one - step purification of biochemically active fusion proteins, Applied and Environmental Microbiology, August 1996, pp. 3057-3060, Vol. 62, No. 8	
1	114	LOPEZ, et al., Architecture and domain interchange of the pneumococcal cell wall lytic enzymes, Genetics of Streptococci, Enterococci and Lactococci, Developments in Biological Standardization, 1995, pp. 273-281, Vol. 85	
1,	115	LOPEZ, et al., The pneumococcal cell wall degrading enzymes a modular design to create new lysins, Microbial Drug Resistance, November 2, 1997, pp. 199-211, Vol. 3, No. 2	
NS	116	MARTIN, et al., Functional analysis of the two-gene lysis system of the pnemococcal phage Cp-1 in homologous and heterologous host cells, Journal of Bacteriology, January 1998, pp. 210-217, Vol. 180, No. 2	

Examiner	00	Date	1
Signature	1	Considered	04-26-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0851-0031
S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

Example 1 of the Paperwork Reduction Act of 1995, no persons at the paperwork Reduction Act of 1995, no p

In use Diffice: U.S. DEFF... sation unless it contains a value Series it co Substitute for form 1449A/PTO Complete if Known **Application Number** INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor

Group Art Unit

Examiner Name

JUN 1 1 2003

(use as many sheets as necessary)

of 11 Sheet Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CAMPAGE 1		MUKHLIS, et al., Characterization and Immunogenicity of HSV-1 antigens obtained following zwitteronic detergent treatment; Vaccine, September 1986, pp. 191-196, Vol. 4	
	118	NELSON, et al., Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme, PNAS, March 27, 2001, pp. 4107-4112, Vol. 98, No. 7	
	119	NELSON, et al., Selective and rapid killing of group A streptococci using a muralytic enzyme, Database Biosis Online, Biosciences Information Service, Philadelphia, PA, US and abstracts of the General Meeting of the American Society for Microbiology, 2000, pp. 32-33	
	120	OKI, et al., Functional and structural features of the holin HOL protein of the Lactobacillus plantarum phage analysis in escherichia coli system, Gene, 1997, pp. 137-145, Vol. 197	
	121	OKUHARA, et al., Preparation of group A streptococcal cell membranes by treatment with group C streptococcus phage - associated lysin, Annales Paediatrici Japonici, June 1983, pp. 10-19, Vol. 29, No. 2	
	122	PATTON, et al., Routes of delivery: case studies, Pulmonary delivery of peptides and proteins for systemic action, Advanced Drug Delivery Reviews, 1992, pp. 179-196, Vol. 8	
	123	POLAK, et al., In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant staphylococcus aureus, Diagn. Microbiol. Infect. Dis., 1993, pp. 265-270, Vol. 17	
	124	RAINA, Punification of streptococcus group C bacteriophage lysin, Journal of Bacteriology, January 1981, pp. 861-663, Vol. 145, No. 1	
	125	RONDA, et al., Infection of streptococcus oralis NCTC 11427 by pneomococcal phages, FEMS Microbiology Letters, 1989, pp. 187-192, Vol. 65	
	126	SANZ, et al., Construction of a multifunctional pneumococcal murein hydrolase by module assembly, Eur. J. Biochem., Fabruary 1, 1996, pp. 601-805, Vol. 235, No. 3	
1115	127	SATO, et al., Partial characterization of n - Butanol - solubilized rejection - type entigens of syngeneic murine colon tumors, JNCI, April 1985, Vol. 74, No. 4	

Examiner	10	Date	[
Signature	201	Considered	14-26-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

•		Underth	ne Paperwo	nk Redu	JUN 1	Apprint and Trades are required respond to a collection of	roved for use through 10/31/2 mark Office: U.S. DEPARTME information unless it contains a vi-	ENT OF COMMERCE	1
1	Substitute	for form 1	449A/PTO)	61	ADEM	Complete if Known		1
			-101		01 001105	Application Number	09/960,472	R	>
					CLOSURE	Filing Date	09/21/01	44	FCA.
	STAT	EME	NT B	YA	PPLICANT	First Named Inventor	Vincent Fischetti	.//.	CIVE
						Group Art Unit	1652	7~	
	((use as n	nany she	ets as	necessary)	Examiner Name	David J. Steadman	ECHON	27003
	Sheet	10		of	11	Attorney Docket Number		LIVIZ	303
			0	THE	R PRIOR ART NO	N PATENT LITERATURE	DOCUMENTS	(4)	1600/2900
1		1	Inchi	ıda na	me of the author (in CA)	PITAL LETTERS) title of the a	rticle (when annioniate)	title of [1

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
rs	128	SHEEHAN, et al., Analysis of the catylytic domain of the lysin of the lactococcal bacteriophage Tuc2009 by chimeric gene assembling; FEMS Microbiology Letters, 1996, pp. 23-28, Vol. 140	
	129	SHEEHAN, et al., The lytic enzyme of the pneumococcal phage Dp-1: A chimeric lysin of intergeneric origin, Molecular Microbiology, 1997, pp. 717-725	
	130	WITTE, et al., Characterization of escherichia coli lysis using a family of chimeric E-L genes, FEMS Microbiology Letters, 1998, pp. 159-167, Vol. 164	
	131	YARNALL, et al., Isolation and partial characterization of a type II Fc receptor from a group A streptococcus, Molecular and Cellular Biochemistry, 1986, pp. 57-68, Vol. 70	
DIS	132	CISANI, et al., High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme, Antimicrobial Agents and Chemotherapy, April 1982, pp. 531-535, Vol.21, No. 4	
			~

			والماك المناسب والرائد والماك المناسب والرائد والمناسبة
Examiner	10	Date	
Signature	25	Considered	04-26-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 11 Sheet

	Complete if Known	
Application Number	09/960,472	OIPE
Filing Date	09/21/01	
First Named Inventor	Vincent Fischetti	
Group Art Unit	1652	JIN 1 1 200°
Examiner Name	David J. Steadman	- 12
Attorney Docket Number		3
		PACEMAR

			U.S. PATENT D	OCUMENTS		
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials *	No.'	Number - Kind Code ² (if known)	MM-DD-YYYY	<u></u>		
1215	133	US-5605793	02/25/97	Stemmer	Figures Appear	
1	134	US- 6355477	03/12/02	Fischetti et al		Ch
	135	US- 8331405	12/18/01	Rambukkana et al		~/ J
	136	US- 6190659	02/20/01	Pancholi et al	"ON"	
 	137	US- 5985654	11/16/99	Fischetti et al		
1-	138	US- 5842314	11/24/98	Scott et al	-07 Can	?003
_	139	US- 5910441	06/08/99	Rocha et al	LAVIER 160	
1	140	US- 5788205	07/28/98	Fischetti et al	<i>~'' /6</i> b	0/2
	141	US-5976792	11/02/99	Cheung et al		1/29
 	142	US- 5821088	10/13/98	Darzins et al		-,
 	143	US- 5723303	03/03/98	Fischetti et al		
1	144	US- 5643767	07/01/97	Fischetti et al		
1	145	US- 5707822	01/13/98	Fischetti et al		
1	146	US- 5616686	04/01/97	Fischetti et al		
 	147	US-5604109	02/18/97	Fischetti et al		
1-	148	US- 5587288	12/24/96	Cheung et al		
1	149	US- 5556944	09/17/96	Fischetti et al		
 	150	US- 5352588	10/04/94	Fischetti et al		
.//	151	US- 5968763	10/19/99	Fischetti et al		
7115	152	US- 4784948	11/15/88	Scott et al		

FOREIGN PATENT DOCUMENTS								
	F	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T⁰		
DIS	153	WO 03/024410 A2	03/27/03	Fischetti et al				
				L				
	1				ļ			
]		1		J i			

4				
1	Examiner	1 00	Date	1
ł		1/4-	Considered	14-26-04
ı	Signature	1692	Considered	04-26-04
•				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

JAN 1 8 2001
TECH CENTER 1600/2900
Patent/Application N

LIST OF NEW HORIZON PATENTS AND PATENT APPLICATIONS

	Pat. No. 6,506,954 954 App.No. 09/395,636 (Cert. of Correction)	App. No. 6,586,954 App. No. 09/395,636 Cert. of Correction) App. No. 6,238,661 App. No. 09/497,495
U.S.A.	U.S.A.	U.S.A. U.S.A.
02-25-99	02-25-99	02-25-99 09-14-99 04-18-00
11-16-99	11-16-99	11-16-99 05-02-00 05-29-01
Fischetti Loomis		μ.
Streptococcal Infections Prophylactic and Therapeutic Treatment of App of Group A Streptococcal Infections	Streptococcal Infections Prophylactic and Therapeutic Treatment of App of Group A Streptococcal Infections Use of Bacterial Phage Associated Lysing Enzymes for the Prophylactic and Therapeutic Treatment of Various Illnesses	Streptococcal Infections Prophylactic and Therapeutic Treatment of App of Group A Streptococcal Infections Use of Bacterial Phage Associated Lysing Enzymes for the Prophylactic and Therapeutic Treatment of Various Illnesses Use of Bacterial Phage Associated Lysing Enzymes for Treating Various Illnesses
02-25-99 11-16-99 Fischetti Loomis	Pat. No. 5,985,271 Pat. No. 5,985,271 U.S.A. 02-25-99 11-16-99 Loomis (Cert. of Correction) Pat. No. 6,506,954 Pat. No. 6,506,954 U.S.A. 09-14-99 05-02-00 Fischetti App.No. 09/395,636 (Cert. of Correction)	Pat. No. 5,985,271 Pat. No. 6,985,271 Pat. No. 6,506,954,757 Pat. No. 6,506,954,757 U.S.A. 09-14-99 05-02-00 App.No. 09/395,636 (Cert. of Correction) Pat. No. 6,238,661 App. No. 09/497,495 U.S.A. 04-18-00 05-29-01 Fischetti Loomis Loomis
	Pat. No. 6,596,954 954 U.S.A. 09-14-99 05-02-00 Fischetti App.No. 09/395,636 Loomis (Cert. of Correction)	Pat. No. 6,506,954 7574 U.S.A. 09-14-99 05-02-00 Fischetti App.No. 09/395,636 Loomis (Cert. of Correction) Pat. No. 6,238,661 U.S.A. 04-18-00 05-29-01 Fischetti Loomis

04-26-04

Treatment of Bacterial Infections

•	DUS	200	sid	DIS	SUG	STA	sra .	SIA	DIS
	Pat. No. 6,248,324	.App. No. 09/671,880	App. No. 09/671,881	Pat. No. 6,277,399 App. No. 09/671,882	App. No. 09/654,482	Pat. No. 6,254,866 App. No. 09/653,690	App. No. 09/654,483	App. No. 09/654,484	Pat. No. 6,056,955 App. No.09/395,637
	U.S.A.	U.S.A.	U.S.A.	U.S.A.	U.S.A.	U.S.A.	U.S.A.	U.S.A.	U.S.A.
	09-28-00	09-28-00		09-28-00	09-01-00	09-01-00	09-01-00	09-11-00	09-14-99
3	06-19-01			08-21-01		07-03-01			05-02-00
	Fischetti	Fischetti Loomis	Fischetti Loomis	Fischetti Loomis	Fischetti Loomis	Fischetti Loomis	Fischetti Loomis	Trudil	Fischetti Loomis
	Bacterial Phage Associated Lysing	A Composition for Treatment of An- Ocular Bacterial Infection	A Composition for Treatment of Vaginal Bacterial Infections	Compositions Incorporating Bacterial Phage Associated Lysing Enzymes For Treating Dermatological Infections	A Composition for Treatment of a Bacterial Infection of the Digestive Tract	Use of Phage Associated Lytic Enzymes For Treating Bacterial Infections of the Digestive Tract	A Composition for Treatment of A Bacterial Infection of An Upper Respiratory Tract	——The Use of Phage Associated Lytic Enzymes For the Rapid Detection of Bacterial	Topical Treatment of Streptococcal Infections

40-52-40

sia	as as	DVS .	DIS		Sid	Sign	23	Ø
NS App. No. 09/752,731	App. No. 09/560,650	App. No. 09/704,148	Pat. No. 6,326,002 App. No. 09/671,990	NOTE: THE USPTO PRINTED THE WRONG TITLE AND THE WRONG CLAIMS	Pat. No. 6,335,012 App. No. 09/671,992	App. No. 09/671,991	App. No. 09/671,878	App. No. 09/671,879
U.S.A.	U.S.A.	U.S.A.	U.S.A.	RINTED THI	U.S.A.	U.S.A.	U.S.A.	
01-03-01	04-28-00	11-02-00	09-28-00	E WRONG TIT	09-28-00	09-28-00	09-28-00	
			12-04-01	LE AND THE W	01-01-02		÷	
Fischetti Loomis	Fischetti Loomis	Fischeni Loomis Trudil	Fischetti Loomis	RONG CLAIMS	Fischetti Loomis	Fischetti Loomis	Fischetti Loomis	Loomis
The Parental Use of Bacterial Phage Associated Lysing Enzymes For The Lysing Enzymes for the Therapeutic	The Use of Bacterial Phage Associated Lysing Enzymes for the Prophylactic and Therapeutic Treatment of Various Illnesses	The Use of Bacterial Phage Associated Lytic Enzymes to Prevent Food Poisoning	The Use of Bacterial Phage Associated Lysing Enzymes for Treating Bacterial Infections of the Upper Respiratory System		A Method for Treating Dental Caries Caused by Streptococcus Mutans	A Composition for Treating Dental Caries Caused by Streptococcus Mutans	The Use of Bacterial Phage Associated Lytic Enzymes for Treating Dermatological Infections	Enzymes to Treating Dermatological Infections

40-92-40

Treatment of Bacterial Infections

Di	Sla	SIG	Sid	SIG	DH DH
App. No. 09/844,435 U.S.A.	· App. No. 09/910,940 U.S.A.	App. No. 09/908,737 U.S.A.	App. No. 09/960,472 U.S.A.	Prov. No. 60/324,089 U.S.A.	DG App. No. 09/932,460 U.S.A.
04-30-01	07-13-01	07-19-01	09-24-01	09-24-01	07-13-01
Fischetti Loomis	Eischetti Loomis	Eischetti Loomis	Fischetti Loomis	Fischetti Loomis	Fischetti Loomis
The Use of Bacterial Phage Associated Lysing Enzymes For	The Use of Bacterial Phage Associated Lytic Enzymes to Prevent Food Poisoning	Parenteral Use of Bacterial Phage Associated Lysing Enymes for the Therapeutic Treatment of Bacterial Infections	The Use of Bacterial Phage Associated Lysing Enzymes for the Prophylactic and Therapeutic Treatment of Colonization and Infections Caused by Streptococcus pneumoniae	The Use of Bacterial Shuffled and Chimeric Phage Associated Lytic Enzymes for the Prophylactic and Therapeutic Treatment of Colonization and Infections caused By Streptococcus Pneumoniae	The Use of Bacterial Phage Associated Lysing Enzymes for Treating Various Illnesses

Af 04-26-04

Treating Various Illnesses

				_	₽
			`	5	36
145087 28767199	\$14260 2001-700898 200105279-4	2000-600679- 2001126302 not yet filed	WA 99909595.3	PCT/US99/04063	App. No. 09/846,688 U.S.A.
- CHINA - CHINA	NEW ZEALAND NORTH KOREA SINGAPORE	JAPAN- RUSSIAN FEDERATION -POLAND BDAZU-	TROIX	PCT	8 U.S.A.
*	AND REA	EDERATION		02-25-99	05-02-01
			Loomis	Fischetti	Fischetti Loomis
			Therapeutic Treatment of Streptococcal Infections	A Means for the Prophylactic and	The Use of Bacterial Phage Associated Lysing Proteins for the Prophylactic and Therapeutic Treatment of Various Illnesses

ff - 04-26-04